Mga Batayang Estadistika
| LEI | 549300XYJQJDSQZ0AY81 |
| CIK | 1815974 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Anebulo Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13E-3 (Rule 13e-100) RULE 13e-3 TRANSACTION STATEMENT UNDER SECTION 13(e) OF THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. ) Anebulo Pharmaceuticals, Inc. (Name of the Issuer and Name of Person Filing Statement) Common Stock, $0.001 par value per share (Title of Class of Securities) 034569103 (CUSIP Number of Cla |
|
| July 23, 2025 |
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock Exhibit 99.1 Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock July 23, 2025 8:00 am EST AUSTIN, Texas-(BUSINESS WIRE)- Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced that a Special Committee |
|
| July 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| July 23, 2025 |
Exhibit 107 Calculation of Filing Fee Table SC 13E-3 Table 1 - Transaction Valuation Anebulo Pharmaceuticals, Inc Transaction Valuation Fee Rate Amount of Filing Fee Fees to Be Paid $ 1,450,001 (1) 0. |
|
| May 15, 2025 |
As filed with the Securities and Exchange Commission on May 15, 2025 As filed with the Securities and Exchange Commission on May 15, 2025 Registration No. |
|
| May 15, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Anebulo Pharmaceuticals, Inc. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| May 13, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 13, 2025 |
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates AUSTIN, Texas (May 13, 2025) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the three mo |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 14, 2025 |
Amendment to the Amended and Restated Bylaws of Anebulo Pharmaceuticals, Inc. Exhibit 3.3 AMENDMENT TO THE AMENDED AND RESTATED Bylaws OF ANEBULO PHARMACEUTICALS, INC. 1. Section 17 of the Bylaws is hereby amended and restated in its entirety as follows: Section 17. Election of Directors. Each director, other than any who may be elected by the holders of any series of Preferred Stock under specified circumstances, at the annual meeting of stockholders of the Corporation tha |
|
| April 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commis |
|
| April 14, 2025 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANEBULO PHARMACEUTICALS, INC. Anebulo Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: One: The name of the Corporation is Anebulo Pharmaceuticals, Inc. |
|
| April 14, 2025 |
Exhibit 3.2 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANEBULO PHARMACEUTICALS, INC. Anebulo Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: One: The name of the Corporation is Anebulo Pharmaceuticals, Inc. |
|
| April 7, 2025 |
Amendment to the Anebulo Pharmaceuticals, Inc. 2020 Stock Incentive Plan Exhibit 10.1 AMENDMENT TO THE ANEBULO PHARMACEUTICALS, INC. 2020 Stock Incentive Plan Whereas, the Board of Directors (the “Board”) of Anebulo Pharmaceuticals, Inc. (the “Company”) heretofore established the Anebulo Pharmaceuticals, Inc. 2020 Stock Incentive Plan (the “Plan”); and Whereas, the Board desires to amend the Plan to increase the maximum number of shares of the Company’s common stock, p |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| March 3, 2025 |
15,151,514 Shares of Common Stock Filed Pursuant to Rule 424(b)(5) Reg. No. 333-285098 PROSPECTUS 15,151,514 Shares of Common Stock This prospectus relates to the resale from time to time of up to an aggregate of 15,151,514 shares of common stock, par value $0.001 per share (the “Common Stock”), of Anebulo Pharmaceuticals, Inc. by the selling stockholders identified in this prospectus (the “Selling Stockholders”), including their |
|
| February 26, 2025 |
February 26, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 24, 2025 |
Lock-Up Agreement, dated February 24, 2025, by and between the Company and 22NW Fund, LP Exhibit 10.1 LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (the “Agreement”) is made and entered into as of the 24th day of February, 2025, between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and 22NW Fund, LP, sometimes referred to herein as the “Stockholder.” For all purposes of this Agreement, “Stockholder” includes any “affiliate, controlling person of Stockholder, agent, |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| February 24, 2025 |
Irrevocable Instruction Letter, dated February 24, 2025 Exhibit 10.2 February 24, 2025 VIA ELECTRONIC MAIL Continental Stock Transfer & Trust 17 Battery Place New York, New York 10004 Re: Irrevocable Transfer Agent Instructions Ladies and Gentlemen: Reference is made to that certain Securities Purchase Agreement, dated December 22, 2024 (the “Purchase Agreement”), entered into by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “C |
|
| February 20, 2025 |
As filed with the Securities and Exchange Commission on February 20, 2025. As filed with the Securities and Exchange Commission on February 20, 2025. Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 ANEBULO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 2834 85-1170950 (State or other jurisdiction of incorporation |
|
| February 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Anebulo Pharmaceuticals, Inc. |
|
| February 14, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2025 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| February 14, 2025 |
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates AUSTIN, Texas (February 14, 2025) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the th |
|
| February 14, 2025 |
Amended and Restated Loan Agreement Exhibit 10.2 AMENDED AND RESTATED LOAN AGREEMENT THIS AMENDED AND RESTATED LOAN AGREEMENT (this “Agreement”) is dated as of February 10, 2025 (the “Effective Date”) among (a) 22NW, LP (“22NW”), in its capacity as the administrative agent and collateral agent (“Agent”) pursuant to the Prior Agreement (defined below), (b) 22NW, LP, as a lender pursuant to the Prior Agreement and as assignor of all r |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 ANEBULO PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 26, 2024 |
SCHEDULE A Transactions in the Shares of Common Stock by the Reporting Persons Within the Last Sixty Days Nature of the Transaction Shares of Common Stock Purchased/(Sold) Price Per Share ($) Date of Purchase/Sale Purchase of Common Stock by 22NW Fund, LP 10,101,010 0.99 12/23/2024 |
|
| December 23, 2024 |
Exhibit 99.1 Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise AUSTIN, Texas (December 23, 2024) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced toxicities (the “Company” or “Anebulo”), t |
|
| December 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 22, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| December 23, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of December [●], 2024, by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the ter |
|
| November 13, 2024 |
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates AUSTIN, Texas (November 13, 2024) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results for the thr |
|
| November 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| October 17, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 17, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Comm |
|
| October 17, 2024 |
Anebulo Pharmaceuticals, Inc. Corporate Presentation, dated October 17, 2024 Exhibit 99.1 |
|
| September 25, 2024 |
Exhibit 97.1 |
|
| September 25, 2024 |
Exhibit 19.1 Anebulo Pharmaceuticals, Inc. INSIDER TRADING POLICY Persons Covered This Insider Trading Policy of Anebulo Pharmaceuticals, Inc. (the “Company”) applies to all directors, officers, other employees and consultants of the Company and any subsidiaries. It also applies to their family members who reside with them, anyone else who lives in their households and any family members who do no |
|
| September 25, 2024 |
Exhibit 99.1 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas (September 25, 2024) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), today announced financial results fo |
|
| September 25, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| July 22, 2024 |
Exhibit 99.1 Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects AUSTIN, Texas (July 22, 2024) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the “Company” or “Anebulo”), has been awarded the firs |
|
| July 22, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 17, 2024 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 ANEBULO PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or other jurisdiction of incorporation) (Commis |
|
| May 15, 2024 |
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas (May 15, 2024) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid toxicities that include acute cannabinoid intoxication (ACI) and unintentional cannabis poisonin |
|
| May 15, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| February 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| February 13, 2024 |
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas (February 13, 2024) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced finan |
|
| November 21, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT TO THE SECONDED AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANEBULO PHARMACEUTICALS, INC. Anebulo Pharmaceuticals, Inc. (the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), hereby certifies that: One: The name of the Corporation is Anebulo Pharmaceuticals, In |
|
| November 21, 2023 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 Anebulo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or other jurisdiction of incorporation) (Co |
|
| November 14, 2023 |
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates Exhibit.99.1 Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas (November 14, 2023) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financ |
|
| November 14, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| November 14, 2023 |
Exhibit 10.3 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (this “Agreement”) is dated as of November 13, 2023 (the “Effective Date”) among (a) 22NW, LP (“22NW”), in its capacity as administrative agent and collateral agent (“Agent”), (b) 22NW, as a lender, (c) JFL Capital Management LLC (“JFL”) as a lender (22NW, in its capacity as a lender hereunder, JFL and each of the other “Len |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy State |
|
| October 19, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State |
|
| October 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commi |
|
| October 6, 2023 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”), effective as of October 5, 2023 (the “Effective Date”), is made by and between Richard Anthony Cunningham (the “Executive”) and Anebulo Pharmaceuticals, Inc., a Delaware corporation (together with any of its subsidiaries and affiliates as may employ the Executive from time to time, and any successor(s) thereto, the “Com |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 29, 2023 |
Exhibit 10.1 September 25, 2023 Daniel George 16630 Glenn Canyon Ct. Morgan Hill, CA 95037 Re: Employment Terms Dear Daniel: Anebulo Pharmaceuticals, Inc. (the “Company”) is pleased to offer you employment beginning on September 28, 2023 (the “Start Date”). Position Your initial position will be Chief Financial Officer, responsible for performing such duties as are assigned to you from time to tim |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| September 20, 2023 |
Exhibit 99.1 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Recent Updates AUSTIN, Texas (September 20, 2023) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced |
|
| September 20, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 29, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 11, 2023 |
Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Third Quarter Fiscal 2023 Financial Results and Recent Updates AUSTIN, Texas (May 11, 2023) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse (the “Company” or “Anebulo”), today announced financial result |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| May 11, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 11, 2023 |
Exhibit 99.1 |
|
| April 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 28, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 8, 2023 |
Exhibit 10.1 MASTER SERVICES AGREEMENT This Master Services Agreement (the “Agreement”) is made effective as of March 2, 2023 (the “Effective Date”), by and between Anebulo Pharmaceuticals, Inc., a Delaware corporation, with its principal place of business being 1415 Ranch Road 620 South, Suite 201, Lakeway, TX 78734 (the “Company”) and Potrero Hill Advisors, LLC., a California limited liability c |
|
| March 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| February 10, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 10, 2023 |
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2023 Financial Results and Recent Updates AUSTIN, Texas (February 10, 2023) – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial r |
|
| February 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| January 9, 2023 |
EX-99.2 3 ex99-2.htm Exhibit 99.2 Anebulo Pharmaceuticals Announces Completion of Dosing and Preliminary Data from Part B of its Phase 2 Study of ANEB-001 for Acute Cannabinoid Intoxication ● Preliminary data showed ANEB-001 reduced effects of a 30 mg dose of THC ● Delayed dosing of ANEB-001 rapidly reversed pre-existing THC effects ● Full PK, PD, and safety data expected by end of 1Q2023 ● Compan |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 ANEBULO PHARMACEUTICALS, INC (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commi |
|
| January 9, 2023 |
Company Presentation dated January 2023 Exhibit 99.1 |
|
| November 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 10, 2022 |
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2023 Financial Results and Recent Updates AUSTIN, Texas (November 10, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the ?Company? or ?Anebulo?), today announced financial re |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| November 8, 2022 |
Anebulo Pharmaceuticals, Inc. 1415 Ranch Road 620 South, Suite 201 Lakeway, Texas 78734 (512) 598-0931 November 8, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Doris Stacey Gama Re: Anebulo Pharmaceuticals, Inc. Registration Statement on Form S-1 File No. 333-268113 Acceleration Request Requested Dat |
|
| November 2, 2022 |
As filed with the Securities and Exchange Commission on November 2, 2022 As filed with the Securities and Exchange Commission on November 2, 2022 Registration No. |
|
| November 2, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-1 (Form Type) ANEBULO PHARMACEUTICALS, INC. |
|
| October 28, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 Anebulo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or other jurisdiction of incorporation) (Com |
|
| October 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Amendment No. 1 Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defini |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| October 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2022 Anebulo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or other jurisdiction of incorporation) (Com |
|
| October 13, 2022 |
Exhibit 3.1 AMended and restated BYLAWS OF Anebulo Pharmaceuticals, Inc. A delaware corporation (Adopted as of October 11, 2022) ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of busines |
|
| September 29, 2022 |
Exhibit 4.2 THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER APPLICABLE SECURITIES LAWS, OR UNLESS OFFERED, SO |
|
| September 29, 2022 |
Anebulo Pharmaceuticals Announces $6.6 million Private Placement Financing Exhibit 99.1 Anebulo Pharmaceuticals Announces $6.6 million Private Placement Financing AUSTIN, Texas (September 26, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance addiction (the ?Company? or ?Anebulo?), today announced that it has agreed to sell |
|
| September 29, 2022 |
Unregistered Sales of Equity Securities, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 25, 2022 ANEBULO PHARMACEUTICALS, INC (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 29, 2022 |
Exhibit 4.1 EXECUTION VERSION SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this ?Agreement?), dated as of September 25, 2022, is made by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and the Purchasers listed on Exhibit A hereto, together with their permitted transferees (each, a ?Purchaser? and collectively, the ?Purchasers?). RECITALS: A. T |
|
| September 26, 2022 |
Company Presentation dated September 26, 2022 Exhibit 99.1 |
|
| September 26, 2022 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2022 ANEBULO PHARMACEUTICALS, INC (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 9, 2022 |
Employment Agreement, dated January 1, 2021, between Rex Merchant and Anebulo Pharmaceuticals, Inc. Exhibit 10.6 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), effective as of January 1 , 2021 (the ?Effective Date?), is made by and between Rex Merchant (the ?Executive?) and Anebulo Pharmaceuticals, Inc., a Delaware corporation (together with any of its subsidiaries and affiliates as may employ the Executive from time to time, and any successor(s) thereto, the ?Company?). RECIT |
|
| September 9, 2022 |
Exhibit 99.1 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Highlights Recent Business Progress AUSTIN, Texas (September 9, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the ?Company? or ?Anebulo?), to |
|
| September 9, 2022 |
Exhibit 4.4 DESCRIPTION OF SECURITIES The following summary description of the securities of Anebulo Pharmaceuticals, Inc. (?we,? ?our? or ?us?) is based on the provisions of our amended and restated certificate of incorporation (?Restated Certificate?), as well as our amended and restated bylaws (?Restated Bylaws?), and the applicable provisions of the Delaware General Corporation Law. This infor |
|
| September 9, 2022 |
EXHIBIT 3.1 Second AMENDED AND RESTATED Certificate of Incorporation of Anebulo Pharmaceuticals, Inc. a Delaware corporation Anebulo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: A. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of |
|
| September 9, 2022 |
Exhibit 10.2 ANEBULO PHARMACEUTICALS, INC. 2020 STOCK INCENTIVE PLAN Adopted by the board of directors: June 18, 2020 Approved by the stockholders: June 18, 2020 ipo date: may 11, 2021 amendment adopted by the board of directors: October 22, 2021 amendment adopted by the stockholders: october 22, 2021 1. Purpose. The purpose of this 2020 Stock Incentive Plan (the ?Plan?) of Anebulo Pharmaceuticals |
|
| September 9, 2022 |
Exhibit 10.9 Anebulo Pharmaceuticals, Inc. Non-Employee Director Compensation Policy Each member of the Board of Directors (the ?Board?) who is not also serving as an employee of or consultant to Anebulo Pharmaceuticals, Inc. (the ?Company?) or any of its subsidiaries (each such member, an ?Eligible Director?) will receive the compensation described in this Non-Employee Director Compensation Polic |
|
| September 9, 2022 |
Amended and Restated By-laws of Anebulo Pharmaceuticals, Inc. EXHIBIT 3.3 AMENDED AND RESTATED Bylaws of Anebulo Pharmaceuticals, Inc. A Delaware corporation (Adopted as of April 23, 2021) TABLE OF CONTENTS Article 1. Offices 1 Section 1.1. Registered Office 1 Section 1.2. Other Offices 1 Article 2. Stockholders? Meetings 1 Section 2.1. Annual Meeting 1 Section 2.2. Special Meetings 1 Section 2.3. Notice of Stockholder Business and Nominations 1 Section 2.4. |
|
| September 9, 2022 |
Exhibit 3.2 CERTIFICATE OF CORRECTION OF THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANEBULO PHARMACEUTICALS, INC. Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), in accordance with the provisions of Section 103 of the General Corporation Law of the State of Delaware, DOES HEREBY CERTIFY: 1. The name of the Company is Anebulo Pharmaceuticals, Inc. 2. A Se |
|
| September 9, 2022 |
Exhibit 10.8 JFL Capital Management 1415 Ranch Road 620 South, Suite 201 Lakeway, Texas 78734 August 15, 2020 Anebulo Pharmaceuticals Re: Premises at 1415 Ranch Road 620 South Lakeway, Texas 78734 (?Leased Premises?) Daniel: We are the tenant of the Leased Premises, leased by us from Prosperity Bank (?Lessor?), in accordance with the covenants, agreements, terms, provisions and conditions of lease |
|
| September 9, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2022 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| July 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2022 Anebulo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40388 85-1170950 (State or other jurisdiction of incorporation) (Commiss |
|
| July 5, 2022 |
Exhibit 99.2 Anebulo Pharmaceuticals Announces Positive Topline Data for ANEB-001 from a Phase 2 Clinical Trial for Acute Cannabinoid Intoxication ? Study Met Primary Endpoint VAS Feeling High (p < 0.0001) ? Statistically Significant and Sustained Reductions in Key THC-Related CNS Symptoms ? Conference Call 8:30am Eastern Time Today AUSTIN, Texas (July 5, 2022) ? Anebulo Pharmaceuticals, Inc. (Nas |
|
| July 5, 2022 |
Corporate Slide Presentation, dated July 5, 2022 Exhibit 99.1 |
|
| May 24, 2022 |
Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer Exhibit 99.1 Anebulo Pharmaceuticals Appoints Kenneth Cundy, Ph.D., as Chief Scientific Officer AUSTIN, Texas (May 24, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the ?Company? or ?Anebulo?), today announced the appointment of |
|
| May 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2022 ANEBULO PHARMACEUTICALS, INC. |
|
| May 24, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), effective as of May 20, 2022 (the ?Effective Date?), is made by and between Kenneth Cundy (the ?Executive?) and Anebulo Pharmaceuticals, Inc., a Delaware corporation (together with any of its subsidiaries and affiliates as may employ the Executive from time to time, and any successor(s) thereto, the ?Company?). RECITALS |
|
| May 11, 2022 |
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates AUSTIN, Texas (May 11, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the ?Company? or ?Anebulo?), today announced financial results |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| May 11, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 22, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Anebulo Pharmaceuticals, Inc. |
|
| April 22, 2022 |
As filed with the U.S. Securities and Exchange Commission on April 21, 2022 As filed with the U.S. Securities and Exchange Commission on April 21, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Anebulo Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 85-1170950 (State or other jurisdiction of incorporation or organizatio |
|
| April 1, 2022 |
Exhibit 99.1 Anebulo Pharmaceuticals Doses More Than Half of the Subjects in Part A of a Phase 2 Clinical Trial and Provides Guidance on IND Submission AUSTIN, Texas (April 1, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the ?Co |
|
| April 1, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 1, 2022 ANEBULO PHARMACEUTICALS, INC. |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| February 11, 2022 |
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates Exhibit 99.1 Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2022 Financial Results and Recent Updates AUSTIN, Texas (February 11, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the ?Company? or ?Anebulo?), today announced financial r |
|
| February 11, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2022 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 5, 2022 |
Exhibit 10.1 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), effective as of February 1, 2022 (the ?Effective Date?), is made by and between Simon Allen (the ?Executive?) and Anebulo Pharmaceuticals, Inc., a Delaware corporation (together with any of its subsidiaries and affiliates as may employ the Executive from time to time, and any successor(s) thereto, the ?Company?). RECITA |
|
| January 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2021 ANEBULO PHARMACEUTICALS, INC. |
|
| January 5, 2022 |
Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director Exhibit 99.1 Anebulo Pharmaceuticals Names Biotechnology Industry Executive Simon Allen as CEO and Director AUSTIN, Texas (January 4, 2022) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse, has named Simon Allen as Chief Executive Officer and a member of |
|
| January 3, 2022 |
Exhibit 99.1 Anebulo Pharmaceuticals Announces Initiation of Phase 2 Clinical Study Evaluating ANEB-001 for the Treatment of Acute Cannabinoid Intoxication Affirms expectations for initial topline results in 1H 2022 Recent FDA pre-IND meeting provides valuable guidance on U.S. regulatory path; company expects to submit IND in 1Q 2022 AUSTIN, Texas (January 3, 2022) ? Anebulo Pharmaceuticals, Inc. |
|
| January 3, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 3, 2022 ANEBULO PHARMACEUTICALS, INC. |
|
| November 16, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2021 ANEBULO PHARMACEUTICALS, INC. |
|
| November 12, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits 8-K 1 form8-k.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2021 ANEBULO PHARMACEUTICALS, INC (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of I |
|
| November 12, 2021 |
Exhibit 99.1 Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2022 Financial Results and Provides a Business Update AUSTIN, Texas (November 12, 2021) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced financial results for the |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| September 22, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2021 ANEBULO PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-40388 85-1170950 (State or Other Jurisdiction of Incorporation) (C |
|
| September 22, 2021 |
Exhibit 99.1 September 22, 2021 Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides a Business Update AUSTIN, Texas (September 22, 2021) ? Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance addiction, today announced |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| September 22, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. |
|
| June 21, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 or [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. |
|
| May 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. )1 Anebulo Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 034569103 (CUSIP Number) ARON R. |
|
| May 17, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the shares of Common Stock, $0.001 par value, of Anebulo Pharmaceuticals, Inc., a Delaware corporation. |
|
| May 10, 2021 |
3,000,000 Shares Anebulo Pharmaceuticals, Inc. Common Stock Filed Pursuant to Rule 424(b)(4) Registration No. 333-254979 PROSPECTUS 3,000,000 Shares Anebulo Pharmaceuticals, Inc. Common Stock This is the initial public offering of common stock of Anebulo Pharmaceuticals, Inc. We are offering 3,000,000 shares of our common stock. Prior to this offering, no public market has existed for our common stock. The initial public offering price of our common stock |
|
| May 5, 2021 |
May 5, 2021 VIA EDGAR TRANSMISSION Division of Corporate Finance United States Securities and Exchange Commission 100 F Street, N. |
|
| May 5, 2021 |
8-A12B 1 form8a-12b.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 ANEBULO PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 85-1170950 (State or other jurisdiction of incorporation or organization) (I.R. |
|
| May 5, 2021 |
Email: [email protected] Direct Dial: 212.451.2234 May 5, 2021 VIA EDGAR AND ELECTRONIC MAIL U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn.: Division of Corporation Finance Office of Life Sciences Re: Anebulo Pharmaceuticals, Inc. Amendment No. 1 to Registration Statement on Form S-1 Filed April 26, 2021 File No. 333-254979 Ladies and Gentlemen: On behal |
|
| May 5, 2021 |
As filed with the U.S. Securities and Exchange Commission on May 5, 2021 Registration No. 333-254979 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 2 to FORM S-1 REGISTRATION STATEMENT under the Securities Act of 1933 Anebulo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or |
|
| May 5, 2021 |
ANEBULO PHARMACEUTICALS, INC. 1415 Ranch Road 620 South, Suite 201 Lakeway, Texas 78734 CORRESP 1 filename1.htm Email: [email protected] DIRECT DIAL: 212.451.2234 May 5, 2021 VIA EMAIL AND EDGAR U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Margaret Schwartz, Esq., Division of Corporation Finance, Office of Life Sciences Re: Anebulo Pharmaceuticals, Inc. Registration Statement on Form S-1 (No. 333-254979) Registration Statement on F |
|
| April 26, 2021 |
EXHIBIT 3.4 AMENDED AND RESTATED Bylaws of Anebulo Pharmaceuticals, Inc. A Delaware corporation (Adopted as of , 2021) TABLE OF CONTENTS Article 1. Offices 1 Section 1.1. Registered Office 1 Section 1.2. Other Offices 1 Article 2. Stockholders? Meetings 1 Section 2.1. Annual Meeting 1 Section 2.2. Special Meetings 1 Section 2.3. Notice of Stockholder Business and Nominations 1 Section 2.4. Notice |
|
| April 26, 2021 |
Filed Pursuant to Rule 433 Issuer Free Writing Prospectus Registration Statement File No. 333-254979 |
|
| April 26, 2021 |
Email: [email protected] Direct Dial: 212.451.2234 April 26, 2021 VIA EDGAR AND ELECTRONIC MAIL U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn.: Division of Corporation Finance, Office of Life Sciences Re: Anebulo Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed April 1, 2021 File No. 333-254979 Ladies and Gentlemen: On behalf of Anebulo Pha |
|
| April 26, 2021 |
EXHIBIT 3.3 Second AMENDED AND RESTATED Certificate of Incorporation of Anebulo Pharmaceuticals, Inc. a Delaware corporation Anebulo Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Corporation?), hereby certifies as follows: A. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of |
|
| April 26, 2021 |
As filed with the U.S. Securities and Exchange Commission on April 26, 2021 Registration No. 333-254979 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT under the Securities Act of 1933 Anebulo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation |
|
| April 26, 2021 |
Form of Underwriting Agreement Exhibit 1.1 [?] Shares1 Anebulo Pharmaceuticals, Inc. Common Stock, par value $0.001 per share UNDERWRITING AGREEMENT [?], 2021 THE BENCHMARK COMPANY, LLC As Representative of the several Underwriters named in Schedule I hereto c/o The Benchmark Company, LLC 150 East 58th St., 17th Floor New York, New York 10155 Ladies and Gentlemen: Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Comp |
|
| April 1, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANEBULO PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Anebulo Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY |
|
| April 1, 2021 |
Exhibit 10.6 AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT This Amendment No. 1 to the Employment Agreement (this ?Amendment?) is made as of the 22nd day of January, 2021 (the ?Effective Date?) by and between Daniel Schneeberger, whose address is 7816 Lynchburg Drive, Austin, TX 78738 (the ?Employee?) and Anebulo Pharmaceuticals, Inc. (the ?Company?). WHEREAS, the Company and Employee entered into an Em |
|
| April 1, 2021 |
Code of Ethics for the CEO and Senior Financial Officers Exhibit 14.2 ANEBULO PHARMACEUTICALS, INC. (the ?Company?) CODE OF ETHICS FOR THE CEO AND SENIOR FINANCIAL OFFICERS The Company has a Code of Business Conduct and Ethics applicable to all directors and employees of the company. The Chief Executive Officer and all senior financial officers, including the Chief Financial Officer and principal accounting officer, are bound by the provisions set forth |
|
| April 1, 2021 |
Anebulo Pharmaceuticals, Inc. 2020 Stock Incentive Plan, and Form of Award Agreement thereunder Exhibit 10.7 ANEBULO PHARMACEUTICALS, INC. 2020 STOCK INCENTIVE PLAN 1. Purpose. The purpose of this 2020 Stock Incentive Plan (the ?Plan?) of Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to t |
|
| April 1, 2021 |
Exhibit 10.9 CONSULTANCY AGREEMENT THIS CONSULTANCY AGREEMENT is dated July 15, 2020 BETWEEN: (1) Traxeus Pharma Services Limited a company registered in England with a registered office at 85 Great Portland Street, London W1W 7LT (?TRAXEUS?); and (2) Anebulo Pharmaceuticals Inc a company registered in Deleware, USA and having a place of business at 1415 Ranch Road 620 South, Suite 201 Lakeway, Te |
|
| April 1, 2021 |
Exhibit 10.2 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this ?Agreement?), is made as of the 18th day of June, 2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), the Investors (as defined below) listed on Schedule A and the Key Holders (as defined below) listed on Schedule B. WHEREAS, each Key Holder is the |
|
| April 1, 2021 |
As filed with the U.S. Securities and Exchange Commission on April 1, 2021 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT under the Securities Act of 1933 Anebulo Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation or Organization) 2834 (Pri |
|
| April 1, 2021 |
Exhibit 10.1 SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this ?Agreement?), is made as of the 18th day of June, 2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), the investors listed on Exhibit A attached to this Agreement (each a ?Purchaser? and together the ?Purchasers?). The parties hereby agree as follows: |
|
| April 1, 2021 |
Exhibit 4.2 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI |
|
| April 1, 2021 |
Exhibit 4.1 NUMBER Incorporated under the Laws of the State of Delaware SHARES ANEBULO PHARMACEUTICALS, INC. SHARES OF COMMON STOCK AUTHORIZED CAPITAL, 3,800,000 SHARES, COMMON STOCK, PAR VALUE $0.001 PER SHARE SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP No. XXXXXXXXXX THIS CERTIFIES THAT IS THE OWNER OF of the Capital Stock of ANEBULO PHARMACEUTICALS, INC., designated as Common Stock transferable o |
|
| April 1, 2021 |
Exhibit 10.3 INVESTORS? RIGHTS AGREEMENT THIS INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of the 18th day of June, 2020, by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?, and any Additional Purchaser (as defined in the Purchase Agr |
|
| April 1, 2021 |
Email: [email protected] Direct Dial: 212.451.2234 April 1, 2021 VIA EDGAR AND E-MAIL Division of Corporation Finance U.S. Securities and Exchange Commission Mail Stop 3628 100 F Street, N.E. Washington, D.C. 20549 Attn: Margaret Schwartz, Esq., Office of Life Sciences Re: Anebulo Pharmaceuticals, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted March 12, 2021 . Ladi |
|
| April 1, 2021 |
Exhibit 10.8 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of [insert date] between Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and [insert name of indemnitee] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unle |
|
| April 1, 2021 |
Code of Ethics and Business Conduct Exhibit 14.1 ANEBULO PHARMACEUTICALS, INC. (the ?Company?) CODE OF ETHICS AND BUSINESS CONDUCT Introduction This Code of Ethics and Business Conduct (?Code?) covers a wide range of business practices and procedures. It does not cover every issue that may arise, but it sets out basic principles to guide the directors, officers, and employees of the Company. All Company directors, officers, and empl |
|
| April 1, 2021 |
Exhibit 10.4 LICENCE AGREEMENT Dated 26 May 2020 (1) Vernalis (R&D) Limited (2) Anebulo Pharmaceuticals, Inc. CONTENTS Page 1 Definitions 2 2 Licence 12 3 Conduct of Development and Commercialisation 14 4 Diligence and Reporting 15 5 Fees, Milestone and Royalty Payments 17 6 Intellectual Property ? Ownership 22 7 Intellectual Property ? Prosecution and Maintenance 22 8 Representation, Warranties a |
|
| April 1, 2021 |
Exhibit 4.3 THIS WARRANT AND THE SECURITIES ISSUABLE UPON THE EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, HYPOTHECATED, OR OTHERWISE TRANSFERRED EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY THAT REGI |
|
| April 1, 2021 |
Exhibit 3.2 BY-LAWS OF ANEBULO PHARMACEUTICALS, INC. Table of Contents Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 General Powers 5 2.2 Nu |
|
| April 1, 2021 |
Exhibit 21.1 SUBSIDIARIES OF THE REGISTRANT Name of Subsidiary Name of Parent Company Subsidiary State of Organization None. |
|
| April 1, 2021 |
Exhibit 10.5 EMPLOYMENT AGREEMENT This Employment Agreement (the ?Agreement?), effective as of July 21, 2020 (the ?Effective Date?), is made by and between Daniel Schneeberger (the ?Executive?) and Anebulo Pharmaceuticals, Inc., a Delaware corporation (together with any of its subsidiaries and affiliates as may employ the Executive from time to time, and any successor(s) thereto, the ?Company?). R |
|
| March 12, 2021 |
BY-LAWS OF ANEBULO PHARMACEUTICALS, INC. Table of Contents Exhibit 3.2 BY-LAWS OF ANEBULO PHARMACEUTICALS, INC. Table of Contents Page ARTICLE I STOCKHOLDERS 1 1.1 Place of Meetings 1 1.2 Annual Meeting 1 1.3 Special Meetings 1 1.4 Notice of Meetings 1 1.5 Voting List 1 1.6 Quorum 2 1.7 Adjournments 2 1.8 Voting and Proxies 2 1.9 Action at Meeting 3 1.10 Conduct of Meetings 3 1.11 Action without Meeting 4 ARTICLE II DIRECTORS 5 2.1 General Powers 5 2.2 Nu |
|
| March 12, 2021 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ANEBULO PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Anebulo Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY |
|
| March 12, 2021 |
RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT Exhibit 10.2 RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT THIS RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this ?Agreement?), is made as of the 18th day of June, 2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), the Investors (as defined below) listed on Schedule A and the Key Holders (as defined below) listed on Schedule B. WHEREAS, each Key Holder is the |
|
| March 12, 2021 |
LICENCE AGREEMENT 26 May 2020 (1) Vernalis (R&D) Limited (2) Anebulo Pharmaceuticals, Inc. Exhibit 10.4 LICENCE AGREEMENT Dated 26 May 2020 (1) Vernalis (R&D) Limited (2) Anebulo Pharmaceuticals, Inc. CONTENTS Page 1 Definitions 2 2 Licence 12 3 Conduct of Development and Commercialisation 14 4 Diligence and Reporting 15 5 Fees, Milestone and Royalty Payments 17 6 Intellectual Property ? Ownership 22 7 Intellectual Property ? Prosecution and Maintenance 22 8 Representation, Warranties a |
|
| March 12, 2021 |
DRS/A 1 filename1.htm Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on March 12, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Confidential |
|
| March 12, 2021 |
ANEBULO PHARMACEUTICALS, INC. 2020 STOCK INCENTIVE PLAN Exhibit 10.6 ANEBULO PHARMACEUTICALS, INC. 2020 STOCK INCENTIVE PLAN 1. Purpose. The purpose of this 2020 Stock Incentive Plan (the ?Plan?) of Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to t |
|
| March 12, 2021 |
Exhibit 10.3 INVESTORS? RIGHTS AGREEMENT THIS INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of the 18th day of June, 2020, by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?, and any Additional Purchaser (as defined in the Purchase Agr |
|
| March 12, 2021 |
SERIES A PREFERRED STOCK PURCHASE AGREEMENT Exhibit 10.1 SERIES A PREFERRED STOCK PURCHASE AGREEMENT THIS SERIES A PREFERRED STOCK PURCHASE AGREEMENT (this ?Agreement?), is made as of the 18th day of June, 2020 by and among Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), the investors listed on Exhibit A attached to this Agreement (each a ?Purchaser? and together the ?Purchasers?). The parties hereby agree as follows: |
|
| March 11, 2021 |
March 12, 2021 VIA EDGAR AND ELECTRONIC MAIL U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Attn.: Division of Corporation Finance, Office of Life Sciences Re: Anebulo Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Submitted January 29, 2021 CIK No. 0001815974 Ladies and Gentlemen: On behalf of Anebulo Pharmaceuticals, Inc., a Delaware corporation ( |
|
| January 29, 2021 |
Confidential Draft Submission No. 1 submitted to the Securities and Exchange Commission on January 29, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Confidential Draft Submission No. |
|
| January 29, 2021 |
January 29, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Anebulo Pharmaceuticals, Inc. Draft Registration Statement on Form S-1 Ladies and Gentlemen: On behalf of Anebulo Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), we hereby confidentially submit through EDGAR one complete copy of Confidentia |
